Improved cumulated nitrogen balance after administration of recombinant human growth hormone in patients undergoing gastrointestinal surgery.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

To examine the effect of recombinant human growth hormone (rhGH) on the catabolic state following major gastrointestinal surgery.

Who Took Part

The study group was 39 patients.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Intensive care unit and the surgical ward of the Department of Surgery, Städtische Kliniken Dortmund, FRG.

The patients were 40-75 years old.

How the Study Was Run

The design is described as randomized, single-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Only one side, usually the patients, was kept unaware of whether Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was given.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

The study was designed as a prospective controlled randomized clinical trial.

Resting energy expenditure (REE) on the 1st postoperative day was 2,042 +/- 82 kcal/24 h (REE/BEE 1.44 +/- 0.04).

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diverticulitis, Colonic, Gastrectomy, Gastrointestinal Diseases, Growth Hormone, Insulin-Like Growth Factor I and Nitrogen.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 39 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1994 (Infusionstherapie und Transfusionsmedizin), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.